Compare Johnson & Johnson (JNJ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Neurocrine Biosciences Inc — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Johnson & Johnson is far larger — about 43× Neurocrine Biosciences Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Neurocrine Biosciences Inc for 23 Days on average.
| JNJ | NBIX | |
|---|---|---|
Market Cap | $618.09B | $14.36B |
Volume | 6,050,983 | 1,237,180 |
Sector | Health | Health |
52-Week High | $278.43 | $185.50 |
52-Week Low | $186.00 | $123.10 |
Typical Hold Time | 129 Days | 23 Days |
Enterprise Value | $646.37B | $14.37B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
